Pairnomix, a member of the Patient-Empowered Precision Medicine Alliance (PEMPA) recognized by the White House, today reported on the successful launch of its unique characterization and drug screening services that provide physicians with data on a patient’s rare genetic mutation and on potential treatment options that are currently available.
Pairnomix’ initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. The Company plans to present a case study at the upcoming American Epilepsy Society annual meeting in December.
“Pairnomix was formed to address an unmet need for patients seeking personalized genetic research on their specific mutation,” said Matthew Fox, CEO, Pairnomix. “We look forward to sharing an example of our work later this year and serving patients for years to come.”
In addition to evaluating all patient inquiries, Pairnomix offers immediately available characterization and drug screening services for the following genes:
ADCY5 • CHRNA4 • GABRB3 • GRIN2A • GRIN2B • KCNB1 • KCNQ2 • KCNT1 • SCN2A • SCN8A • SCN9A • SLC2A1
Newly Enhanced Website
The Company has also enhanced its website, pairnomiqstate.wpengine.com, to provide patients and families, healthcare providers and science partners, a more customized and user-friendly experience. The website now includes: a concise, easy-to-understand overview of Pairnomix and its services; expanded resource centers for patients/families and healthcare providers featuring the latest information on genetic testing and genetic research; and a news and events section highlighting up-to-date Company announcements, corporate milestones, media coverage, and upcoming events and speaking engagements.
Upcoming Scientific Meetings
Pairnomix will have a presence at a number of upcoming advocacy and medical meetings including: the KCNQ2 Cure’s 2016 Family and Professional Summit, October 7-9, 2016 in Silver Spring, MD; the Child Neurology Society Annual Meeting, October 26-29, 2016 in Vancouver, BC; and the American Epilepsy Society Annual Meeting, December 2-6, 2016 in Houston, TX.
Pairnomix™, a genetic research company, is committed to helping people living with rare diseases understand the genetic cause of their condition. Pairnomix’ initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit pairnomiqstate.wpengine.com.
MAPLE GROVE, Minn., September 27, 2016 /PRNewswire/